Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.80 and last traded at $13.61, with a volume of 1414936 shares changing hands. The stock had previously closed at $13.66.
Analyst Ratings Changes
Several analysts recently commented on IMMX shares. Lifesci Capital began coverage on shares of Immix Biopharma in a research report on Wednesday, June 17th. They set an "outperform" rating and a $19.00 price target on the stock. Bank of America assumed coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a "buy" rating and a $27.00 target price on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Immix Biopharma in a research note on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of Immix Biopharma in a report on Friday, August 14th. Finally, Morgan Stanley dropped their price objective on Immix Biopharma from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of "Moderate Buy" and a consensus price target of $21.29.
Read Our Latest Stock Analysis on Immix Biopharma
Immix Biopharma Stock Down 0.4%
The company's fifty day moving average is $10.19 and its two-hundred day moving average is $9.34. The stock has a market cap of $973.65 million, a price-to-earnings ratio of -15.47 and a beta of 0.11.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). Sell-side analysts predict that Immix Biopharma, Inc. will post -0.74 EPS for the current fiscal year.
Hedge Funds Weigh In On Immix Biopharma
Several hedge funds and other institutional investors have recently made changes to their positions in IMMX. Allworth Financial LP purchased a new position in Immix Biopharma in the fourth quarter valued at about $30,000. Legal & General Group Plc acquired a new stake in shares of Immix Biopharma during the second quarter worth $41,000. Mathes Company Inc. bought a new position in Immix Biopharma in the fourth quarter worth about $56,000. Compass Financial Management LLC acquired a new position in Immix Biopharma during the 2nd quarter valued at approximately $56,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Immix Biopharma during the fourth quarter worth about $67,000. Institutional investors and hedge funds own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
